“Through CRISPR RNA optimization, we achieved around 59% editing at the TTR locus in our in vitro experiments. In the mouse ...

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR technologies in the field of regenerative medicine. The study, authored by ...

Intellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the JP Morgan Healthcare ...

CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...

Scientists have used CRISPR to give the goldenberry a modern makeover, shrinking the plant by about a third and making it easier to farm. Goldenberries are tasty and nutritious but notoriously unruly, ...

Victoria Gray, the first patient treated with CRISPR, and Jennifer Doudna, the CRISPR pioneer, at the 2025 Liberty Science Center's Genius Gala. In a recent conversation with Nobel Prize winning ...

CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...

Despite pipeline setbacks and slow CASGEVY rollout, future revenue acceleration and expansion into cardiovascular and autoimmune diseases offer significant long-term growth opportunities. CRISPR ...

CRISPR Therapeutics has an approved gene-therapy treatment still in its early growth stages. The company isn't profitable, but has a strong cash position, which can help buy a lot of time. One of the ...